Oliver Rossi In my 'Sell' report published in April 2024, I highlighted IDEXX's (NASDAQ:IDXX) high-quality business in consumables and software, as well as the stock's hefty valuation. IDEXX reported its Q2 result on August 6th, lowering the full-year organic revenue growth to 6.2% - 7.8% for FY24. The guidance cut is primarily caused by reduced U.S. clinical visits. While I think the lower clinical visits are maero-driven and short-term in nature, the stock price remains overvalued and has not fully accoun ...